Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

A long-term study suggests GLP-1 agonists, especially semaglutide, may lower the risk of alcohol use disorder hospitalizations, highlighting the potential for novel treatments pending further ...

Ozempic Wegovy Zepbound Potential Benefits of GLP-1 Agonists GLP-1 medications offer a range of potential health benefits, specifically for those with type 2 diabetes or those looking to lose weight.

GLP-1 agonists, including liraglutide, are typically used to control blood sugar levels in type 2 diabetes and to promote weight loss. These drugs mimic a hormone released after eating, helping to ...

GLP-1 receptor agonists that are prescribed once weekly, such as semaglutide, dulaglutide, and long-acting release exenatide, are inactive and half-way eliminated in 5 to 7 days.

These GLP-1 receptor agonists are approved for patients with obesity and for those with a BMI greater than 27 kg/m 2 who are also diagnosed with weight-related conditions, such as hypertension ...

GLP-1 medications, or glucagon-like peptide-1 agonists, are designed to mimic a hormone that the body produces after eating. This mechanism leads to reduced appetite, quicker feelings of fullness, and ...

Asked why GLP-1 receptor agonists would influence such a diverse set of medical conditions, Al-Aly said a few different mechanisms might be at play. For one, it could be that addressing obesity by ...

GLP-1 receptor agonists are already being used to treat alcohol use disorder in some circumstances, Dr. Sarhan says, noting that this is a growing trend in addiction disorder medicine.

Patients prescribed GLP-1 agonists also had a 22% lower risk for cirrhosis complications (1.89 vs 2.55 events per 1,000 person-years; HR 0.78, 95% CI 0.59-1.04) and an 11% lower risk for all-cause ...

GLP-1 receptor agonists have been shown to reduce allergic airway inflammation and viral-induced airway inflammation,” Katherine N. Cahill, MD, medical director of clinical asthma research in ...